Takeda Pharmaceutical (TAK) reported a non-GAAP EPS of ¥428.00 for the nine-month period, with revenue totaling ¥3,411.2 billion, marking a 3.3% year-over-year decrease. The company has revised its FY2025 management guidance, citing factors like VYVANSE contributions, cost management, and favorable foreign exchange impacts. The updated forecast anticipates revenue of ¥4,530.0 billion, a slight increase from the previous projection of ¥4,500.0 billion. Operating profit is expected to reach ¥410.0 billion, while EPS is forecasted at ¥98.
https://www.gurufocus.com/news/8561441/takeda-tak-updates-fy2025-guidance-amid-revenue-adjustments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.